Research programme: anxiety and depression therapeutics - Affectis Pharmaceuticals/Evotec AG
Latest Information Update: 30 Jul 2007
Price : $50
At a glance
- Originator Affectis Pharmaceuticals; Evotec AG
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 31 Jan 2005 Affectis received a grant of €750,000 from German state funder tbg Technologie-Beteiligungs-Gesellschaft mbH for Affectis' drug discovery and development programmes .
- 31 Jan 2005 Neuronova AG is now called Affectis Pharmaceuticals
- 17 Jun 2004 Preclinical trials in Depression in United Kingdom (unspecified route)